+91-8668442535

Mantle Cell Lymphoma Treatment Market By Mechanism Of Action (Bruton’s Tyrosine Kinase Blocker (Ibrutinib), Angiogenesis Inhibitor (Lenalidomide), CD20 Antigen Inhibitor (Rituximab), mTOR Protein Inhibitor (Temsirolimus), Proteasome Inhibitors (Bortezomib), Phase III Drug, Tabular Representation Of Phase II And I Drugs) - Growth, Future Prospects & Competitive Analysis, 2017 – 2025

The World Health Organization has reported the incidence rate of mantle cell lymphoma globally as 0.5 cases per 100,000 people. Mantle cell lymphoma has an aggressive etiology that usually commences with the enlargement of a lymph node and progresses to metastasis to other organs such as the bone marrow, gastrointestinal tract, and liver. Mantle cell lymphoma is resistant to chemotherapeutic drug treatment, so a targeted treatment approach has been adopted with promising drugs in the product pipeline with better efficacy and safety, e.g., Zydelig, Gazyva, Abemaciclib, and KTE-C19.

To understand the drug regimen used for the treatment of mantle cell lymphoma, the drugs are segmented on the basis of their mechanisms of action: Bruton’s Tyrosine Kinase Blocker (ibrutinib), Angiogenesis Inhibitor (lenalidomide), CD20 Antigen Inhibitor (rituximab), mTOR Protein Inhibitor (temsirolimus), and Proteasome Inhibitors (bortezomib). A brief description of the market size and forecast is available for the above segment.

To understand the performance of drugs employed for the treatment of mantle cell lymphoma in the regional segments, their respective major countries have been considered in the segment.

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • Italy
    • U.K.
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • India
    • China
    • Japan
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East and Africa

Country-level cross-sectional market estimates and forecasts for the geography segment have been included in the scope of the report.

The most important aspect is to understand that a promising pipeline will result in competition among the prominent players to have a significant hold on the mantle cell. In order to understand the competitive environment in the development of drugs for the treatment of mantle cell lymphoma, we need to consider the competitive landscape. The latest mergers or acquisitions and purchases of promising drug molecules are mentioned in the company profile section. The major players in the global mantle cell lymphoma treatment market are Celgene Corporation, Abbvie, Inc., Astellas Pharma, Inc., Biogen, Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline Plc, Amgen, Inc., Gilead Sciences, Inc., Johnson & Johnson, and F. Hoffmann-La Roche Ltd.

Based on the mechanism of action, the mantle cell lymphoma treatment market is categorized into:

  • Bruton’s Tyrosine Kinase Blocker (Ibrutinib)
  • angiogenesis inhibitor (Lenalidomide)
  • CD20 Antigen Inhibitor (Rituximab)
  • mTOR Protein Inhibitor (Temsirolimus)
  • Bortezomib (Proteasome Inhibitors)
  • Phase III drug
  • Acalabrutinib
  • Bendamustine, Rituximab, and Ibrutinib (Qualitative Information)
  • Ibrutinib/Venetoclax (qualitative information)
  • Lenalidomide and Rituximab (Qualitative Information)
  • Rituximab/Bortezomib (qualitative information)
  • Tabular Representation of Phase II and I Drugs

Mantle cell lymphoma is distinguished by the overexpression of cyclin D1, which is engaged in the stimulation of cell growth due to the translocation being caused between chromosomes 11 and 14. The occurrence of mantle cell lymphoma is approximately 3–6% of newly diagnosed cases of non-Hodgkin’s lymphoma. It is metastatic in nature, with clinical manifestations reported as highly aggressive and involving the extranodal engagement of the gastrointestinal tract and bone marrow. Rituximab has been approved as the first line of treatment along with chemotherapy drugs such as cyclophosphamide, doxorubicin, vincristine, and prednisone.

The dominance of rituximab is due to the increasing number of non-Hodgkins patients diagnosed with CD20 antigen, considered a marker for mantle cell lymphoma. Obinutuzumab (Roche) will be considered to replace rituximab for the treatment of mantle cell lymphoma. Bortezomib and lenalidomide will most likely be subjected to generic completion during the forecast period of 2017–2025. Ibrutinib will be showcasing significant growth and is set to be the market leader in the treatment of mantle cell lymphoma due to the increasing cases of relapsed mantle cell lymphoma and its ability to promote apoptosis of the tumor cells. The prominent players in the mantle cell lymphoma treatment market are Bristol-Myers Squibb Company, Abbvie, Inc., Celgene Corporation, Amgen, Inc., Astellas Pharma, Inc., Biogen, Inc., Bayer AG, Eli Lilly and Company, GlaxoSmithKline Plc, Gilead Sciences, Inc., Johnson & Johnson, and F. Hoffmann-La Roche Ltd.

North America is currently dominating the global market for mantle cell lymphoma treatment. According to the research findings of the Leukemia and Lymphoma Society, in 2014, there were around 4,200 cases of mantle cell lymphoma. The advancement in diagnostic procedures has resulted in the efficient mapping of mantle cell lymphoma cases in patients suffering from non-Hodgkin’s lymphoma, which benefits the U.S. market. The market growth in Europe is mainly attributed to the increase in patients over 60 years of age diagnosed with mantle cell lymphoma. The European Medicines Agency provides a favorable regulatory environment for drugs used to treat mantle cell lymphoma. Asia Pacific will enjoy impressive market growth due to the increasing number of patients suffering from mantle cell lymphoma, which shows a relative association with Borrelia burgdorferi infection and genetic predisposition. The Asian Pacific market will reap the profits from the generic competition that will be faced by bortezomib and lenalidomide during the period 2015–2025. High spending to raise government-aided hospitals and research centers to treat blood malignancies drives growth in the Middle East, Africa, and Latin America.

Frequently Asked Question:

The market for Mantle Cell Lymphoma Treatment Market is expected to reach USD$ XX in 2025.

The Mantle Cell Lymphoma Treatment Market is expected to see significant CAGR growth over the coming years, at 4.8 %.

The report is forecasted from 2017 -2025.

The base year of this report is 2016.

ACelgene Corporation, Abbvie, Inc., Astellas Pharma, Inc., Biogen, Inc., Bayer AG, Bristol-Myers Squibb Company, Eli Lilly and Company. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Dec 2017
Category:  Pharmaceuticals
Report ID:   58886
Report Format:   PDF
Pages:   120
Rating:    4.8 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support